With a market cap of $736.1 billion, Eli Lilly and Company (LLY) is a leading American pharmaceutical firm headquartered in ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

U.S. energy firms seek exemption from Trump to transport LNG on U.S.-built ships. China Airlines orders Boeing passenger and ...

Eli Lilly & Co.’s shares fell 6% early Thursday after the drugmaker cut its full-year earnings outlook citing research costs ...

Wall Street's main indexes declined on Tuesday as investors tried to navigate the uncertainty surrounding U.S. President ...

Wall Street's major indexes faced declines as President Trump's announcement of upcoming pharmaceutical tariffs rekindled ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

US-Japan tariff talks on radar Alphabet falls after ruling Insurers slump after UnitedHealth results S&P 500 +0.13%, Nasdaq -0.13%, Dow -1.33% April 17 (Reuters) - Wall Street stocks ended mixed ...